The ability to pivot will be ‘key’ as pharma’s tariff threat looms

The economy is on solid footing, interest rates are dropping and the stars are aligning for pharma companies to offset patent expirations with new drugs. But amid these favorable market dynamics lies a weighty uncertainty: tariffs and other economic levers promised by the new presidential administration.

The incoming Trump administration has pledged to impose broad levies, with tariffs as high as 60% on Chinese goods and 20% to 25% on those from Canada and Mexico.